source
- Eli Lilly removes Gaucher disease gene therapy trial from pipeline, citing unmet internal criteriaEli Lilly has announced the removal of a phase 1/2 study testing its GBA1 gene therapy for Gaucher disease type 1. The program was part of the assets acquired when the company bought Prevail Therap…
- Aurora Therapeutics drops PKU program and trims staffAurora Therapeutics, a gene-editing startup founded by Jennifer Doudna, announced it is abandoning its lead phenylketonuria (PKU) program. The decision follows growing competition in the PKU field…